Underweight with 15-20% trim, $650 hard stop, stand aside with new capital until setup-based re-entry triggers
Underweight with 15-20% trim, $650 hard stop on residual, stand aside with new capital, setup-based re-entry ($620-635 pullback or >$700 breakout). This honors: 9/22 lesson that trim is correct; 9/25 lesson that magnitude must respect WC-driven deterioration fragility; 9/23 lesson that lighter initial trims preserve breakout optionality; 9/17 lesson that 50% weight ceiling applies but full exit does not. The aggressive analyst is right that the structural trend has legs; the conservative analyst is right that the setup is stretched; the calibrated response sits between the extremes in magnitude.
| Position | Action |
|---|---|
| Price at $675-682 resistance zone | Trim 15-20% of position to lock in gains from +36% six-month rally |
| Residual position after trim | Hard stop at $650 daily close |
| New capital deployment | Stand aside — breakout R/R at $682.98 is structurally unfavorable (1:0.3 to $692.50, 1:0.5 to $700) |
Thermo Fisher Scientific is a diversified scientific platform compounder in the early innings of a multi-year life-sciences recovery cycle, with three independent growth vectors, institutional conviction, and a textbook bullish technical structure that justifies current valuation levels.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | 539.90 | bullish |
| close_50_sma | 606.82 | bullish |
| close_10_ema | 659.95 | bullish |
| macd | 20.60 | bullish |
| macdh | 3.40 | bullish |
| rsi | 73.55 | neutral |
| vwma | 646.99 | bullish |
| boll_middle | 635.16 | neutral |
| boll_upper | 692.50 | neutral |
| boll_lower | 577.82 | neutral |
| boll_pct_b | 87.9% | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed close above $700 with above-average volume
Then: Re-engage with position per sizing rules
Three independent growth vectors provide diversified compounding opportunities
↩ rebuts: “Bear claim that TMO is a 'one-trick pony exposed to biotech R&D cycles'”
EV: +5.7% · concedes: RSI at 73.55 is technically overbought; %B at 87.9% is elevated; Stock has run 31.6% in 90 days — short-term stretched; PEG of 2.01 looks elevated in isolation; Net debt of $38.5B is elevated for active build mode
TMO is a high-quality business being valued at a low-quality multiple, with bearish momentum divergence, unfavorable risk/reward at resistance, deteriorating balance sheet quality, and macro headwinds that make the current entry point decisively unfavorable for new capital.
· concedes: The business quality is real — TMO is a legitimate platform compounder with genuine moat; The institutional conviction is real — Dodge & Cox and others have done rigorous due diligence; The three growth vectors (Mayo Precure, Gibco CHO-K1, Biodesix MRD) are real incremental revenue streams; The 90-day and 12-month price performance (+31.6%, +39.8%) confirms the trend has been powerful
→ vs conservative: Trim strategy creates worse reward-to-risk than holding (45-point downside vs 20-point upside); framing higher lows as topping pattern is incorrect—in a structural uptrend, repeated resistance tests signal compression and accumulation, not weakness
→ vs conservative: Bearish momentum divergence is unconfirmed—requires price to break 682.98 with lower RSI print; current RSI at 73.55 versus August 75.34 is overbought condition inside strong trend, not confirmed divergence
→ vs conservative: Stop level at 635 and re-entry target at 620-635 requires stock to give back 8-10% from current levels in a name that just rallied 31.6% in 90 days—this pullback may never materialize at targeted levels
→ vs neutral: Receivables divergence of 2,000 basis points is integration noise from $12.87B in acquisitions, not deteriorating collection quality; current ratio 1.55 and $8.3B working capital confirm healthy balance sheet
→ vs neutral: Macro headwinds (higher for longer rates, recession risk) are exactly why TMO's defensive characteristics (0.85 beta, recurring revenue, mega-cap healthcare) make it a shelter play, not a reason to wait on the sidelines
→ vs neutral: Waiting for better entry at 620-635 may result in chasing at 720 when institutional bid absorbs any dip that materializes; patient institutional capital is positioning ahead of multi-quarter earnings beats
| atr | 15.98 | neutral |
Support: 659.95 · 635.16 · 606.82 · 539.9 | Resistance: 682.98 · 692.5 · 700
TMO exhibits a classic golden-cross uptrend with all MAs in bullish alignment, supported by rising VWMA (646.99) confirming genuine buyer participation and MACD in fresh bullish crossover (20.60 vs signal 17.21, histogram +3.40). Short-term overbought conditions (RSI 73.55, %B 87.9%) and failure to break above 9/24 swing high of $682.98 create a "late-stage entry" tape. Recommendation is to HOLD existing positions and add on pullbacks to the 10 EMA ($659.95) rather than chase at current levels near $679, with bull-case invalidation below the 50 SMA at $606.82.
Market Cap
$250.91B
52-Week High
$682.98
52-Week Low
$435.27
50-Day Moving Avg
$604.26
200-Day Moving Avg
$540.22
Beta
0.854
P/E (TTM)
36.56x
Forward P/E
24.64x
Forward EPS
$27.54
TTM EPS
$18.56
PEG Ratio
2.01
P/B
4.76x
Dividend Yield
0.28%
Revenue Q2'26
$11,994M
Gross Profit Q2'26
$4,882M
Operating Income Q2'26
$2,185M
Net Income Q2'26
$1,736M
Diluted EPS Q2'26
$4.68
EBITDA Q2'26
$3,142M
Interest Expense Q2'26
$401M
Revenue YoY (Q2)
+10.5%
EPS YoY (Q2)
+9.3%
Forward EPS Growth
+48.4%
Gross Margin (TTM)
41.0%
Operating Margin (TTM)
18.75%
Net Profit Margin (TTM)
15.04%
EBITDA Margin (TTM)
25.3%
ROE
13.52%
ROA
5.13%
TTM Free Cash Flow
$6.24B
FCF Margin
13.5%
FCF / Net Income Conversion
~90%
CapEx % of Revenue
~3.8%
Total Assets
$113.17B
Goodwill & Intangibles
$73.44B
Net Tangible Assets
-$20.76B
Net PP&E
$10.76B
Current Assets
$23.37B
Inventory
$5.63B
Receivables
$11.14B
Total Liabilities
$60.37B
Long-Term Debt
$39.18B
Current Debt
$3.37B
Total Debt
$42.55B
Cash & Equivalents
$4.06B
Net Debt
$38.49B
Total Equity
$52.81B
Retained Earnings
$62.19B
Debt-to-Equity
80.6%
Current Ratio
1.55
Working Capital
$8.30B
Net Debt / EBITDA
~3.3x
Buybacks Q1+Q2'26
$4.00B
Dividends Q2'26
$175M
M&A Spend (trailing)
~$13B
Goodwill Q2'26
$54.83B
Receivables YoY Growth
~30%
Strengths
Concerns
Thermo Fisher Scientific is a mega-cap healthcare company with a $250.91B market capitalization, providing analytical instruments, specialty diagnostics, and pharmaceutical services across global end markets. The company demonstrated strong Q2'26 results with $11.99B in revenue (+10.5% YoY), $4.68 EPS (+9.3% YoY), and $3.14B EBITDA, supported by 41% gross margins and 18.21% operating margins that expanded year-over-year. The balance sheet shows meaningful leverage (Debt-to-Equity 80.6%, Net Debt/EBITDA 3.3x) driven by ~$13B in acquisitions over the trailing year, with goodwill representing 64.9% of total assets. TMO's capital allocation prioritizes M&A and buybacks over dividends, having deployed $4B in share repurchases in Q1-Q2'26. While the company benefits from defensive characteristics (beta 0.854), a robust FCF profile ($6.24B TTM), and strong ROE (13.52%), the stock trades at a premium (PEG 2.01x) with limited margin of safety if growth disappoints or integration challenges emerge.
Macro: The Federal Reserve is expected to hold rates steady or cut fewer than 6 times in 2026 (97% probability of NO rate cuts), with bond yields continuing to climb on a 'higher-for-longer' path. US recession risk by end of 2026 stands at 8% (up 2pp week-over-week), while UK recession risk is 10% (up 5.5pp WoW). Major US indices declined as Treasury yields pushed higher, with a risk-off backdrop dominating sentiment. The combination of elevated rates and modest but rising recession probability creates a mixed environment for capital-intensive and growth-oriented healthcare assets.